TLE5

Across TCGA pan-cancer cohorts, TLE5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TLE5 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TLE5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TLE5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where TLE5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.770	0.370	<.001	39	view →
CCRCC	DFS	Quartile	III,IV	0.903	0.486	.005	25	view →
UCEC	DFS	Median	III,IV	0.445	0.904	.037	12	view →
GBM	OS	Quartile	All	0.587	0.946	.001	5	view →
HNSC	DFS	Median	IV	1.000	0.413	.033	3	view →
LSCC	DFS	Tertile	II,III,IV	0.482	1.000	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TLE5–PDAC (OS)

Open the PDAC breakdown →